Key Details
Price
$21.26Annual Revenue
$330.53 MAnnual EPS
-$1.06Annual ROE
-14.01%Beta
1.94Events Calendar
Next earnings date:
Feb 27, 2025Recent quarterly earnings:
Nov 06, 2024Recent annual earnings:
Feb 27, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Denali Therapeutics' unique blood-brain barrier technology and strategic partnerships offer a significant edge in the challenging neurodegenerative disease landscape. The company's strong cash position and disciplined financial strategy support its ambitious R&D and commercialization efforts without immediate need for additional funding. Denali's pipeline targets critical neurodegenerative pathways, with promising candidates for lysosomal storage disorders, Parkinson's disease, and neuroinflammation.
DNLI reports a wider-than-expected loss in the third quarter of 2024. Nonetheless, the pipeline progress has been encouraging.
Denali Therapeutics (DNLI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
DNLI's recent meeting with the FDA was successful and provides the path to file for accelerated approval of tividenofusp alfa for the treatment of MPS II and its subsequent conversion to full approval.
Denali Therapeutics (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
The United States population is aging faster than ever, attracting interest in longevity stocks. By 2030, one in five Americans will be a senior citizen, up from one in twenty 100 years ago.
Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock?
Denali's (DNLI) DNL126, an investigational enzyme replacement therapy, gets selected for the START Pilot Program, intended to accelerate the development of rare disease therapies.
Denali Therapeutics Inc. is currently investigating DNL-310 in a phase 2/3 COMPASS study for patients with MPS II, with enrollment completion anticipated in 2024. The company is in discussions with the FDA's CDER division to pursue the Accelerated Approval pathway for DNL-310 in MPS II. Data on biomarkers and safety from a phase 1/2 study using DNL-126 for MPS IIIA patients is expected by the end of 2024.
Denali Therapeutics (DNLI) has experienced positive changes in earnings estimates in the last month and is part of a robust industry.
FAQ
- What is the primary business of Denali Therapeutics?
- What is the ticker symbol for Denali Therapeutics?
- Does Denali Therapeutics pay dividends?
- What sector is Denali Therapeutics in?
- What industry is Denali Therapeutics in?
- What country is Denali Therapeutics based in?
- When did Denali Therapeutics go public?
- Is Denali Therapeutics in the S&P 500?
- Is Denali Therapeutics in the NASDAQ 100?
- Is Denali Therapeutics in the Dow Jones?
- When was Denali Therapeutics's last earnings report?
- When does Denali Therapeutics report earnings?
- Should I buy Denali Therapeutics stock now?